Creative Medical rises on regulatory nod for therapy trials in Type 1 diabetes

Creative Medical Technology Holdings

08/02/2023 14:03

** Shares of drug developer Creative Medical Technology
Holdings Inc  CELZ.O  more than double to $1.31 premarket 
    ** Co says the Institutional Review Board (IRB) has given
approval to proceed with an early-stage trial for its
experimental cell therapy, CELZ-201, in the treatment of Type 1
diabetes   
    ** IRB review and approval are to ensure protection of
rights and welfare of patients participating as subjects in a
biomedical research -CELZ
    ** Co says trial will be conducted at the University of
Miami Health System in conjunction with the Diabetes Research
Institute 
    ** The U.S. FDA in November cleared the co's IND application
to proceed with initiating a clinical trial for Type 1 Diabetes
using AlloStem, co's proprietary product used in CELZ-201 study
    ** Up to Tuesday's close, stock fell ~71% in the past 12
months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))